Following some recent media coverage, we've received many expressions of interest in LIFNano treatment or participation in clinical trials. We're doing our best to reply to each one, but it would be much appreciated if you could read these Frequently Asked Questions before using the Contact email address to get in touch. Thank you!

Q:   How can I obtain treatment or register to participate in clinical trials?
A:   There is still a lot of work to do before clinical trials can commence (provisionally scheduled for 2020). This work, and the deliberately slow process of regulatory approval, are essential to ensure the safety of all patients, and sadly we cannot offer any accelerated access to treatment or early registration for the trials.

Q:   I live outside of the UK - will I be able to participate in the clinical trials?
A: The trial protocol will be designed closer to clinical trials, and we cannot currently offer any advice about where they may take place.

Q:   Should I avoid any other treatments in case they disqualify me from clinical trials of LIFNano?
A:   Please follow the advice of your healthcare provider.

Q:   Will the LIFNano treatment also work for other neurodegenerative or autoimmune diseases?
A:   Currently we're remaining tightly focused on targeting Multiple Sclerosis, but we are optimistic about potential applications in the future, targeting some other neurodegenerative or autoimmune diseases. However, we are still a small company and it's unlikely that we will be able to broaden the scope of our work before a couple of years.

Q:   How can I invest in LIFNano Therapeutics?
A:   Please refer to our Investor Relations page for more information.

Q:   Can I make a donation, or volunteer to do fundraising work or to raise awareness?
A: If you are interested in making a donation, please click here. We are linking with the UK MS Register and will be providing updates on progress, also via our social media channels.

Q:   How can I receive progress updates?
A:   You can learn more about LIFNanoRx on this website, and you can also follow our Facebook page and Twitter feed to receive updates and news.